X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (626) 626
humans (623) 623
dihydrouracil dehydrogenase - genetics (398) 398
female (353) 353
male (340) 340
oncology (283) 283
5-fluorouracil (261) 261
dihydropyrimidine dehydrogenase (261) 261
middle aged (259) 259
aged (238) 238
adult (204) 204
fluorouracil (191) 191
dihydrouracil dehydrogenase - metabolism (183) 183
dihydrouracil dehydrogenase (170) 170
chemotherapy (167) 167
thymidylate synthase - genetics (160) 160
fluorouracil - adverse effects (155) 155
fluorouracil - therapeutic use (154) 154
thymidylate synthase (146) 146
cancer (134) 134
pharmacogenetics (133) 133
toxicity (127) 127
pharmacology & pharmacy (126) 126
antimetabolites, antineoplastic - therapeutic use (123) 123
genotype (113) 113
antimetabolites, antineoplastic - adverse effects (112) 112
oxidoreductases - genetics (112) 112
colorectal neoplasms - drug therapy (110) 110
mutation (102) 102
aged, 80 and over (101) 101
colorectal-cancer (94) 94
capecitabine (89) 89
animals (88) 88
fluorouracil - administration & dosage (87) 87
fluorouracil - pharmacology (86) 86
neoplasms - drug therapy (86) 86
polymorphism, genetic (86) 86
thymidine phosphorylase (85) 85
colorectal cancer (83) 83
colorectal neoplasms - genetics (83) 83
dpd deficiency (83) 83
thymidylate synthase - metabolism (83) 83
enzymes (74) 74
prognosis (72) 72
fluorouracil - metabolism (71) 71
reverse transcriptase polymerase chain reaction (71) 71
dpyd (68) 68
gene (68) 68
gene-expression (66) 66
thymidine phosphorylase - genetics (66) 66
antineoplastic combined chemotherapy protocols - therapeutic use (64) 64
fluorouracil - pharmacokinetics (63) 63
gene expression (63) 63
rna, messenger - genetics (63) 63
rna, messenger - metabolism (63) 63
dihydropyrimidine dehydrogenase-deficiency (61) 61
antimetabolites, antineoplastic - pharmacology (60) 60
deficiency (59) 59
oxidoreductases - metabolism (59) 59
genetic aspects (58) 58
polymorphism, single nucleotide (56) 56
colorectal neoplasms - enzymology (55) 55
colorectal neoplasms - pathology (55) 55
polymerase chain reaction (55) 55
oxidoreductases - deficiency (53) 53
cancer-patients (52) 52
research (52) 52
treatment outcome (51) 51
analysis (49) 49
5-fluorouracil toxicity (48) 48
care and treatment (48) 48
expression (48) 48
genetics & heredity (48) 48
identification (48) 48
medicine & public health (48) 48
deoxycytidine - analogs & derivatives (47) 47
gene expression regulation, neoplastic (47) 47
biochemistry & molecular biology (46) 46
fluorouracil - analogs & derivatives (46) 46
tumors (46) 46
orotate phosphoribosyltransferase - genetics (45) 45
phenotype (45) 45
point mutation (44) 44
polymorphism (44) 44
dihydropyrimidine dehydrogenase deficiency (43) 43
dihydrouracil dehydrogenase - biosynthesis (43) 43
mice (43) 43
antimetabolites, antineoplastic - pharmacokinetics (40) 40
cell line, tumor (40) 40
gene frequency (40) 40
pharmacokinetics (40) 40
base sequence (39) 39
population (39) 39
alleles (38) 38
dihydropyrimidine dehydrogenase gene (38) 38
dpd (38) 38
rna, messenger - analysis (38) 38
antimetabolites, antineoplastic - metabolism (37) 37
neoplasms - genetics (37) 37
predictive value of tests (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (613) 613
Japanese (18) 18
Chinese (8) 8
French (5) 5
German (4) 4
Polish (2) 2
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Italian (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2018, Volume 103, Issue 2, pp. 210 - 216
Journal Article
Journal of Medical Genetics, ISSN 0022-2593, 12/2011, Volume 48, Issue 12, pp. 810 - 818
BackgroundMicroRNAs (miRNAs) are non-coding gene transcripts involved in post-transcriptional regulation of genes. Recent studies identified miRNAs as... 
MESSENGER-RNAS | PROTEIN | MENTAL-RETARDATION | RETT-SYNDROME | GENE | ADULT-MOUSE FOREBRAIN | GENETICS & HEREDITY | TARGETS | LYMPHOBLASTOID CELL-LINES | MICRORNA EXPRESSION | MAMMALIAN-CELLS | Neurons - pathology | Oligonucleotide Array Sequence Analysis | Humans | Male | MicroRNAs - metabolism | Neurons - cytology | DNA Copy Number Variations | Intellectual Disability - genetics | Intellectual Disability - metabolism | DNA-Binding Proteins - metabolism | Transfection | Kruppel-Like Transcription Factors - metabolism | Adult | Female | Neurons - metabolism | Chromosomes, Human, Pair 1 - genetics | Chromosome Deletion | Microphthalmia-Associated Transcription Factor - metabolism | Chromosomes, Human, Pair 1 - metabolism | Gene Expression Regulation | Intellectual Disability - pathology | Rats | Gene Dosage | Hippocampus - pathology | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Hippocampus - cytology | Enhancer of Zeste Homolog 2 Protein | Transcription Factors - metabolism | Hippocampus - metabolism | Phenotype | Polycomb Repressive Complex 2 | Animals | Adolescent | MicroRNAs - genetics | Polymorphism, Single Nucleotide | Primary Cell Culture | Dihydrouracil Dehydrogenase (NADP) - metabolism | Kruppel-Like Transcription Factors - genetics | Microphthalmia-Associated Transcription Factor - genetics | Dihydrouracil Dehydrogenase (NADP) - genetics | Genetic aspects | MicroRNA | Research | Mental retardation | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 13, pp. 2131 - 2138
Journal Article
Clinical cancer research, ISSN 1078-0432, 2011, Volume 17, Issue 10, pp. 3455 - 3468
To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine. Germline DNA... 
IVS14+1G-GREATER-THAN-A MUTATION | 1ST-LINE TREATMENT | MULTICENTER RANDOMIZED-TRIAL | POINT MUTATION | ONCOLOGY | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | FLUOROURACIL PLUS LEUCOVORIN | PHASE-III | SPLICE DONOR SITE | DPD DEFICIENCY | SEVERE 5-FLUOROURACIL TOXICITY | Haplotypes | Capecitabine | Colorectal Neoplasms - genetics | Humans | Middle Aged | Polymorphism, Single Nucleotide - physiology | Male | Case-Control Studies | Antimetabolites, Antineoplastic - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Clinical Trials, Phase III as Topic | Deoxycytidine - therapeutic use | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Drug-Related Side Effects and Adverse Reactions - genetics | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Retrospective Studies | Carcinoma - drug therapy | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Disease Progression | Randomized Controlled Trials as Topic | Antimetabolites, Antineoplastic - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Carcinoma - genetics | Aged | Biomarkers, Tumor - genetics | Biomarkers, Pharmacological - metabolism | Dihydrouracil Dehydrogenase (NADP) - metabolism | Deoxycytidine - analogs & derivatives | Dihydrouracil Dehydrogenase (NADP) - genetics | Cohort Studies | Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2016, Volume 82, Issue 3, pp. 706 - 716
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 01/2014, Volume 443, Issue 3, pp. 789 - 795
5-Fluorouracil (5-FU) is a classic chemotherapeutic drug that has been widely used for colorectal cancer treatment, but colorectal cancer cells are often... 
Chemo-resistance | miR-21 | HT-29 | hMSH2 | 5-FU | DIHYDROPYRIMIDINE DEHYDROGENASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | INVOLVEMENT | MICRORNA-21 | LUNG-CANCER | REPAIR | BIOPHYSICS | COLORECTAL-CANCER | GROWTH | FLUOROPYRIMIDINE | RESISTANCE | EXPRESSION | Colonic Neoplasms - genetics | Apoptosis - radiation effects | Humans | 3' Untranslated Regions - genetics | Molecular Sequence Data | Apoptosis - genetics | MicroRNAs - metabolism | Molecular Targeted Therapy | Chemoradiotherapy | Fluorouracil - therapeutic use | Base Sequence | Thymidine Phosphorylase - genetics | Gene Expression Regulation, Neoplastic - drug effects | Colonic Neoplasms - therapy | Tumor Stem Cell Assay | Neoplasm Invasiveness | Cell Cycle - radiation effects | MutS Homolog 2 Protein - genetics | HT29 Cells | Colonic Neoplasms - pathology | Cell Proliferation - drug effects | Colonic Neoplasms - enzymology | Fluorouracil - pharmacology | MicroRNAs - genetics | Cell Cycle - drug effects | Dihydrouracil Dehydrogenase (NADP) - metabolism | Thymidine Phosphorylase - metabolism | Dihydrouracil Dehydrogenase (NADP) - genetics | Cell Proliferation - radiation effects | Drug Screening Assays, Antitumor | Chemotherapy | Colon cancer | Cancer | Index Medicus | THYMIDINE | LARGE INTESTINE | URACILS | NEOPLASMS | SENSITIVITY | CELL PROLIFERATION | TUMOR CELLS | CHEMOTHERAPY | POLYMERASE CHAIN REACTION | IN VITRO | RADIOLOGY AND NUCLEAR MEDICINE | CELL CYCLE | COMBINED THERAPY
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 11, pp. 1415–1424 - 1424
BACKGROUND: We investigated the predictive value of dihydropyrimidine dehydrogenase (DPD) phenotype, measured as pretreatment serum uracil and dihydrouracil... 
5-fluorouracil | Fluoropyrimidines | Dihydropyrimidine dehydrogenase | Capecitabine | Toxicity | Uracil | toxicity | RATIOS | dihydropyrimidine dehydrogenase | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | CHEMOTHERAPY | capecitabine | PLASMA | COLORECTAL-CANCER PATIENTS | PHARMACOKINETICS | ONCOLOGY | DIHYDROURACIL | fluoropyrimidines | uracil | DPD DEFICIENCY | DPYD VARIANTS | Predictive Value of Tests | Capecitabine - metabolism | Prospective Studies | Humans | Middle Aged | Male | Young Adult | Dihydropyrimidine Dehydrogenase Deficiency - complications | Neoplasms - blood | Dihydropyrimidine Dehydrogenase Deficiency - genetics | Fluorouracil - adverse effects | Drug-Related Side Effects and Adverse Reactions - genetics | Aged, 80 and over | Pharmacogenomic Variants | Adult | Female | Fluorouracil - metabolism | Uracil - blood | Thymidylate Synthase - metabolism | Genotype | Hospitalization | Biomarkers - blood | Pharmacogenomic Testing | Thymidylate Synthase - genetics | Neoplasms - drug therapy | Phenotype | Capecitabine - adverse effects | Alleles | Antimetabolites, Antineoplastic - adverse effects | Leukocytes, Mononuclear - enzymology | Aged | Drug-Related Side Effects and Adverse Reactions - mortality | Dihydrouracil Dehydrogenase (NADP) - metabolism | Dihydrouracil Dehydrogenase (NADP) - genetics | Uracil - analogs & derivatives | Index Medicus | Translational Therapeutics
Journal Article